456 research outputs found
Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems
Introduction Therapeutic drug monitoring (TDM) has been recommended for treatment optimization in tuberculosis (TB) but is only is used in certain countries e.g. USA, Germany, the Netherlands, Sweden and Tanzania. Recently, new drugs have emerged and PK studies in TB are continuing, which contributes further evidence for TDM in TB. The aim of this review is to provide an update on drugs used in TB, treatment strategies for these drugs, and TDM to support broader implementation. Areas covered This review describes the different drug classes used for TB, multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), along with their pharmacokinetics, dosing strategies, TDM and sampling strategies. Moreover, the review discusses TDM for patient TB and renal or liver impairment, patients co-infected with HIV or hepatitis, and special patient populations - children and pregnant women. Expert opinion TB treatment has a long history of using 'one size fits all.' This has contributed to treatment failures, treatment relapses, and the selection of drug-resistant isolates. While challenging in resource-limited circumstances, TDM offers the clinician the opportunity to individualize and optimize treatment early in treatment. This approach may help to refine treatment and thereby reduce adverse effects and poor treatment outcomes. Funding, training, and randomized controlled trials are needed to advance the use of TDM for patients with TB
Exposure to environmentally persistent free radicals during gestation lowers energy expenditure and impairs skeletal muscle mitochondrial function in adult mice
© 2016 the American Physiological Society. We have investigated the effects of in utero exposure to environmentally persistent free radicals (EPFRs) on growth, metabolism, energy utilization, and skeletal muscle mitochondria in a mouse model of diet-induced obesity. Pregnant mice were treated with laboratory-generated, combustion derived particular matter (MCP230). The adult offspring were placed on a high-fat diet for 12 wk, after which we observed a 9.8% increase in their body weight. The increase in body size observed in the MCP230-exposed mice was not associated with increases in food intake but was associated with a reduction in physical activity and lower energy expenditure. The reduced energy expenditure in mice indirectly exposed to MCP230 was associated with reductions in skeletal muscle mitochondrial DNA copy number, lower mRNA levels of electron transport genes, and reduced citrate synthase activity. Upregulation of key genes involved in ameliorating oxidative stress was also observed in the muscle of MCP230-exposed mice. These findings suggest that gestational exposure to MCP230 leads to a reduction in energy expenditure at least in part through alterations to mitochondrial metabolism in the skeletal muscle
Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis
Objectives: The objectives of this study were to explore inter-study heterogeneity in the pharmacokinetics (PK)
of orally administered rifampicin, to derive summary estimates of rifampicin PK parameters at standard dosages
and to compare these with summary estimates for higher dosages.
Methods: A systematic search was performed for studies of rifampicin PK published in the English language up
to May 2017. Data describing the Cmax and AUC were extracted. Meta-analysis provided summary estimates
for PK parameter estimates at standard rifampicin dosages. Heterogeneity was assessed by estimation of the
I
2 statistic and visual inspection of forest plots. Summary AUC estimates at standard and higher dosages were
compared graphically and contextualized using preclinical pharmacodynamic (PD) data.
Results: Substantial heterogeneity in PK parameters was evident and upheld in meta-regression. Treatment
duration had a significant impact on the summary estimates for rifampicin PK parameters, with Cmax 8.98 mg/L
(SEM 2.19) after a single dose and 5.79 mg/L (SEM 2.14) at steady-state dosing, and AUC 72.56 mgh/L
(SEM 2.60) and 38.73 mgh/L (SEM 4.33) after single and steady-state dosing, respectively. Rifampicin dosages of
at least 25 mg/kg are required to achieve plasma PK/PD targets defined in preclinical studies.
Conclusions: Vast inter-study heterogeneity exists in rifampicin PK parameter estimates. This is not explained by
the available modifying variables. The recommended dosage of rifampicin should be increased to improve efficacy. This study provides an important point of reference for understanding rifampicin PK at standard dosages
as efforts to explore higher dosing strategies continue in this field
Comparison of the ‘Denver regimen’ against acute tuberculosis in the mouse and guinea pig
Objectives: In this study, we sought to compare the sterilizing activity of human-equivalent doses of the ‘Denver regimen ’ against acute tuberculosis (TB) infection in the standard mouse model and in the guinea pig. Methods: Pharmacokinetic studies in guinea pigs were used to establish human-equivalent doses for rifampicin, isoniazid and pyrazinamide. Guinea pigs and mice were aerosol-infected with Mycobacterium tuberculosis CDC1551 and treatment was started 2 weeks later with rifampicin/isoniazid/pyrazinamide for up to 6 months. For the first 2 weeks of therapy, the dosing frequency was 5 days/week, and for the remaining period, twice weekly. Treatment was discontinued in groups of 30 mice and 10 guinea pigs at 5 months and at 6 months, and these animals were held for a further 3 months in order to assess relapse rates. Results: Guinea pig lungs became culture-negative after 3 months of predominantly twice-weekly treatment and relapse rates were 0 % (0/10) both after 5 months and after 6 months of treatment. In contrast, all mice remained culture-positive despite 6 months of the same treatment, and 93 % (28/30) and 69 % (20/29) of mice relapsed after treatment for 5 and 6 months, respectively. Conclusions: Treatment with rifampicin/isoniazid/pyrazinamide administered at human-equivalent doses is much more potent against acute TB infection in guinea pigs than in mice. Our findings have importan
How to design a study to evaluate therapeutic drug monitoring in infectious diseases?
Background: Therapeutic drug monitoring (TDM) is a tool to personalize and optimize dosing by measuring the drug concentration and subsequently adjusting the dose to reach a target concentration or exposure. The evidence to support TDM is however often ranked as expert opinion. Limitations in study design and sample size have hampered definitive conclusions of the potential added value of TDM. Objectives: We aim to give expert opinion and discuss the main points and limitations of available data from antibiotic TDM trials and emphasize key elements for consideration in design of future clinical studies to quantify the benefits of TDM. Sources: The sources were peer-reviewed publications, guidelines and expert opinions from the field of TDM. Content: This review focuses on key aspects of antimicrobial TDM study design: describing the rationale for a TDM study, assessing the exposure of a drug, assessing susceptibility of pathogens and selecting appropriate clinical endpoints. Moreover we provide guidance on appropriate study design. Implications: This is an overview of different aspects relevant for the conduct of a TDM study. We believe that this paper will help researchers and clinicians to design and conduct high-quality TDM studies
Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats.
Animal and clinical data show that high ratios of the area under the
concentration-time curve and the peak concentration in blood to the MIC of
fluoroquinolones for a given pathogen are associated with a favorable
outcome. The present study investigated whether improvement of the
therapeutic potential of ciprofloxacin could be achieved by encapsulation
in polyethylene glycol (PEG)-coated long-circulating sustained-release
liposomes. In a rat model of unilateral Klebsiella pneumoniae pneumonia
(MIC = 0.1 microg/ml), antibiotic was administered at 12- or 24-h
intervals at twofold-increasing doses. A treatment period of 3 days was
started 24 h after inoculation of the left lung, when the bacterial count
had increased 1,000-fold and some rats had positive blood cultures. The
infection was fatal within 5 days in untreated rats. Administration of
ciprofloxacin in the liposomal form resulted in delayed ciprofloxacin
clearance and increased and prolonged ciprofloxacin concentrations in
blood and tissues. The ED(50) (dosage that results in 50% survival) of
liposomal ciprofloxacin was 3.3 mg/kg of body weight/day given once daily,
and that of free ciprofloxacin was 18.9 mg/kg/day once daily or 5.1
mg/kg/day twice daily. The ED(90) of liposomal ciprofloxacin was 15.0
mg/kg/day once daily compared with 36.0 mg/kg/day twice daily for free
ciprofloxacin; 90% survival could not be achieved with free ciprofloxacin
given once daily. In summary, the therapeutic efficacy of liposomal
ciprofloxacin was superior to that of ciprofloxacin in the free form.
PEG-coated liposomal ciprofloxacin was well tolerated in relatively high
doses, permitting once daily administration with relatively low
ciprofloxacin clearance and without compromising therapeutic efficacy
Phosphorylation controls autoinhibition of cytoplasmic linker protein-170
Author Posting. © American Society for Cell Biology, 2010. This article is posted here by permission of American Society for Cell Biology for personal use, not for redistribution. The definitive version was published in Molecular Biology of the Cell 21 (2010): 2661-2673, doi:10.1091/mbc.E09-12-1036.Cytoplasmic linker protein (CLIP)-170 is a microtubule (MT) plus-end-tracking protein that regulates MT dynamics and links MT plus ends to different intracellular structures. We have shown previously that intramolecular association between the N and C termini results in autoinhibition of CLIP-170, thus altering its binding to MTs and the dynactin subunit p150Glued (J. Cell Biol. 2004: 166, 1003–1014). In this study, we demonstrate that conformational changes in CLIP-170 are regulated by phosphorylation that enhances the affinity between the N- and C-terminal domains. By using site-directed mutagenesis and phosphoproteomic analysis, we mapped the phosphorylation sites in the third serine-rich region of CLIP-170. A phosphorylation-deficient mutant of CLIP-170 displays an "open" conformation and a higher binding affinity for growing MT ends and p150Glued as compared with nonmutated protein, whereas a phosphomimetic mutant confined to the "folded back" conformation shows decreased MT association and does not interact with p150Glued. We conclude that phosphorylation regulates CLIP-170 conformational changes resulting in its autoinhibition.This work was supported by National
Institutes of Health grant GM-25062 (to G.G.B.); Netherlands Organization for
Scientific Research grants (to A. A. and N. G.); a Cancer Genomics Centre
grant (to J.v.H.); and Presidential Program of Russian Academy of Sciences
and RFBP grant 05-04-4915 (to E.S.N.)
- …